Concordia Healthcare Corp. J (T:CXR)
Business Focus: N/A
Apr 01, 2019 07:00 am ET
ADVANZ PHARMA Corp. Acquires International Rights to Two Medicines
Company acquires international rights to Salagen® tablets (pilocarpine hydrochloride) (excluding Japan rights) and Panretin® (alitretinoin) gel 0.1% from Eisai Inc. for $30 million in cash plus approximately $3.3 million for purchased inventory and related prepayments. ADVANZ PHARMA will pay for the acquisition with cash on hand. MISSISSAUGA, ON, April 1, 2019 /CNW/ - ADVANZ PHARMA Corp. ("ADVANZ PHARMA" or "the Company") (TSX:ADVZ), an international specialty pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with enhanced access to h
Apr 01, 2019 07:00 am ET
ADVANZ PHARMA Corp. Acquires International Rights to Two Medicines
Company acquires international rights to Salagen® tablets (pilocarpine hydrochloride) (excluding Japan rights) and Panretin® (alitretinoin) gel 0.1% from Eisai Inc. for $30 million in cash plus approximately $3.3 million for purchased inventory and related prepayments. ADVANZ PHARMA will pay for the acquisition with cash on hand. MISSISSAUGA, ON, April 1, 2019 /PRNewswire/ - ADVANZ PHARMA Corp. ("ADVANZ PHARMA" or "the Company") (TSX:ADVZ), an international specialty pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with enhanced acce
Nov 29, 2018 04:00 pm ET
Concordia International Corp. Announces Name Change to ADVANZ PHARMA Corp.
MISSISSAUGA, ON, Nov. 29, 2018 /CNW/ - Concordia International Corp. ("Concordia" or "the Company") (TSX: CXR), today announced that shareholders voted in favour of a special resolution authorizing the Company to amend its articles to change its name from Concordia International Corp. to ADVANZ PHARMA Corp. Approximately 99.9 per cent of the votes cast were in favour of the special resolution.
Nov 29, 2018 04:00 pm ET
Concordia International Corp. Announces Name Change to ADVANZ PHARMA Corp.
MISSISSAUGA, ON, Nov. 29, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or "the Company") (TSX: CXR), today announced that shareholders voted in favour of a special resolution authorizing the Company to amend its articles to change its name from Concordia International Corp. to ADVANZ PHARMA Corp. Approximately 99.9 per cent of the votes cast were in favour of the special resolution.
Nov 14, 2018 06:00 am ET
Concordia International Corp. Announces Third Quarter 2018 Results
Third quarter 2018 revenue of $128 million Third quarter net income of $1.8 billion, which includes a $1.9 billion gain on debt settlement as part of the Company's recently completed transaction to realign its capital structure (the "Recapitalization Transaction") Third quarter 2018 Adjusted EBITDA2 of $59 million Generated cash flow from operations of $98 million in the first nine months of 2018 and concluded the third quarter of 2018 with a cash balance of $209 million MISSISSAUGA, ON, Nov. 14, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an intern
Nov 14, 2018 06:00 am ET
Concordia International Corp. Announces Third Quarter 2018 Results
Third quarter 2018 revenue of $128 million Third quarter net income of $1.8 billion, which includes a $1.9 billion gain on debt settlement as part of the Company's recently completed transaction to realign its capital structure (the "Recapitalization Transaction") Third quarter 2018 Adjusted EBITDA2 of $59 million Generated cash flow from operations of $98 million in the first nine months of 2018 and concluded the third quarter of 2018 with a cash balance of $209 million MISSISSAUGA, ON, Nov. 14, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an
Oct 31, 2018 05:00 pm ET
Concordia International Corp. Announces Release Date for Third Quarter 2018 Results
MISSISSAUGA, ON, Oct. 31, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced it intends to release its third quarter 2018 financial results before market open on Wednesday, November 14, 2018.
Oct 31, 2018 05:00 pm ET
Concordia International Corp. Announces Release Date for Third Quarter 2018 Results
MISSISSAUGA, ON, Oct. 31, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced it intends to release its third quarter 2018 financial results before market open on Wednesday, November 14, 2018.
Oct 29, 2018 08:30 am ET
Concordia International Corp. Adds European Pharmaceutical Industry Expert to its Board of Directors
MISSISSAUGA, ON, Oct. 29, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced the election of European pharmaceutical industry expert Maurice Chagnaud to its board of directors, effective November 1, 2018.
Oct 29, 2018 08:30 am ET
Concordia International Corp. Adds European Pharmaceutical Industry Expert to its Board of Directors
MISSISSAUGA, ON, Oct. 29, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced the election of European pharmaceutical industry expert Maurice Chagnaud to its board of directors, effective November 1, 2018.
Oct 15, 2018 05:00 pm ET
Concordia International Corp. Announces Addition of Pharmaceutical Industry Expert to its Board of Directors
MISSISSAUGA, ON, Oct. 15, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that it has appointed pharmaceutical industry expert Frances Cloud to its board of directors. Ms. Cloud's appointment will take effect on November 1, 2018.
Oct 15, 2018 05:00 pm ET
Concordia International Corp. Announces Addition of Pharmaceutical Industry Expert to its Board of Directors
MISSISSAUGA, ON, Oct. 15, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that it has appointed pharmaceutical industry expert Frances Cloud to its board of directors. Ms. Cloud's appointment will take effect on November 1, 2018.
Oct 09, 2018 07:00 am ET
Concordia International Corp. Announces Intention To Rebrand As ADVANZ PHARMA Following Its Successful Recapitalization
- ADVANZ PHARMA represents the Company's vision to go beyond expectations to bring sustainable value to customers, healthcare providers, and patients -
Oct 09, 2018 07:00 am ET
Concordia International Corp. Announces Intention To Rebrand As ADVANZ PHARMA Following Its Successful Recapitalization
- ADVANZ PHARMA represents the Company's vision to go beyond expectations to bring sustainable value to customers, healthcare providers, and patients -
Oct 05, 2018 04:30 pm ET
Concordia International Corp. Announces Special Meeting of Shareholders To Approve Name Change
MISSISSAUGA, ON, Oct. 5, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today issued a notice of meeting (the "Meeting") of shareholders to consider and approve a name change (the "Name Change") of the Company.
Oct 05, 2018 04:30 pm ET
Concordia International Corp. Announces Special Meeting of Shareholders To Approve Name Change
MISSISSAUGA, ON, Oct. 5, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today issued a notice of meeting (the "Meeting") of shareholders to consider and approve a name change (the "Name Change") of the Company.
Sep 12, 2018 08:22 am ET
IIROC Trade Resumption - CXR
TORONTO, Sept. 12, 2018 /CNW/ - Trading resumes in:
Sep 12, 2018 07:48 am ET
Concordia International Corp. Provides Further Update On Its Recently Completed Recapitalization Transaction and the Issue Price of its Private Placement
MISSISSAUGA, ON, Sept. 12, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR) issued a further announcement today, at the request of the Investment Industry Regulatory Organization of Canada (IIROC) and further to the Company's press release issued on September 11, 2018.
Sep 12, 2018 07:48 am ET
Concordia International Corp. Provides Further Update On Its Recently Completed Recapitalization Transaction and the Issue Price of its Private Placement
MISSISSAUGA, ON, Sept. 12, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR) issued a further announcement today, at the request of the Investment Industry Regulatory Organization of Canada (IIROC) and further to the Company's press release issued on September 11, 2018.
Sep 11, 2018 03:10 pm ET
IIROC Trading Halt - CXR
TORONTO, Sept. 11, 2018 /CNW/ - The following issues have been halted by IIROC:
Sep 11, 2018 02:56 pm ET
IIROC Trade Halt - Concordia International Corp.
Toronto, Ontario--(Newsfile Corp. - September 11, 2018) - The following issues have been halted by IIROC:
Sep 11, 2018 01:32 pm ET
IIROC Trade Resumption - Concordia International Corp.
Toronto, Ontario--(Newsfile Corp. - September 11, 2018) - Trading resumes in:
Sep 11, 2018 01:25 pm ET
IIROC Trade Resumption - CXR
TORONTO, Sept. 11, 2018 /CNW/ - Trading resumes in:
Sep 11, 2018 01:18 pm ET
Concordia International Corp. Provides Update On Its Recently Completed Recapitalization Transaction
MISSISSAUGA, ON, Sept. 11, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today at the request of market regulators announced that as part of the Company's recently completed and previously announced recapitalization transaction (the "Recapitalization Transaction"), the Company completed on September 6, 2018, a US$586.5 million private placement for new equity at a price of US$13.69 per limited voting share, as also described in th
Sep 11, 2018 01:18 pm ET
Concordia International Corp. Provides Update On Its Recently Completed Recapitalization Transaction
MISSISSAUGA, ON, Sept. 11, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today at the request of market regulators announced that as part of the Company's recently completed and previously announced recapitalization transaction (the "Recapitalization Transaction"), the Company completed on September 6, 2018, a US$586.5 million private placement for new equity at a price of US$13.69 per limited voting share, as also describe
Sep 11, 2018 09:33 am ET
IIROC Trading Halt - CXR
TORONTO, Sept. 11, 2018 /CNW/ - The following issues have been halted by IIROC:
Sep 06, 2018 09:05 pm ET
Concordia International Corp. Completes Recapitalization Transaction
MISSISSAUGA, ON, Sept. 6, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced the completion of the recapitalization transaction (the "Recapitalization Transaction") described in the Company's management information circular dated May 15, 2018 (the "Circular"), and implemented pursuant to the court-approved plan of arrangement dated June 26, 2018, under the Canada Business Corporations Act (the "CBCA Plan").
Sep 06, 2018 09:05 pm ET
Concordia International Corp. Completes Recapitalization Transaction
MISSISSAUGA, ON, Sept. 6, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced the completion of the recapitalization transaction (the "Recapitalization Transaction") described in the Company's management information circular dated May 15, 2018 (the "Circular"), and implemented pursuant to the court-approved plan of arrangement dated June 26, 2018, under the Canada Business Corporations Act (the "CBCA Plan").
Aug 13, 2018 05:20 pm ET
Concordia International Corp. Announces Update on its Recapitalization Transaction, Filing of Certain Documents in connection with the Implementation of its Recapitalization Transaction and Intention
MISSISSAUGA, ON, Aug. 13, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR) announced today that in connection with the previously announced recapitalization transaction (the "Recapitalization Transaction") to be implemented pursuant to Concordia's plan of arrangement under the Canada Business Corporations Act (the "CBCA Plan"), the Company has substantially finalized the following documents, each of which is to be finalized and executed on the implementation of the Recapitalization Transaction:
Aug 13, 2018 05:20 pm ET
Concordia International Corp. Announces Update on its Recapitalization Transaction, Filing of Certain Documents in connection with the Implementation of its Recapitalization Transaction and Intention
MISSISSAUGA, ON, Aug. 13, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR) announced today that in connection with the previously announced recapitalization transaction (the "Recapitalization Transaction") to be implemented pursuant to Concordia's plan of arrangement under the Canada Business Corporations Act (the "CBCA Plan"), the Company has substantially finalized the following documents, each of which is to be finalized and executed on the implementation of the Recapitalization Transaction:
Aug 08, 2018 07:00 am ET
Concordia International Corp. Announces Second Quarter 2018 Results
- Also Announces Executive Leadership Transition -
Aug 08, 2018 07:00 am ET
Concordia International Corp. Announces Second Quarter 2018 Results
- Also Announces Executive Leadership Transition -
Jul 25, 2018 07:00 am ET
Concordia International Corp. Announces Release Date for Second Quarter 2018 Results
Company also provides anticipated timing update for closing of its Recapitalization Transaction
MISSISSAUGA, ON, July 25, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced it intends to release its second quarter, 2018 financial results before market open on Wednesday, August 8, 2018.
Jul 25, 2018 07:00 am ET
Concordia International Corp. Announces Release Date for Second Quarter 2018 Results
Company also provides anticipated timing update for closing of its Recapitalization Transaction
MISSISSAUGA, ON, July 25, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced it intends to release its second quarter, 2018 financial results before market open on Wednesday, August 8, 2018.
Jul 19, 2018 07:00 am ET
Concordia International Corp. Announces NASDAQ Delisting
Concordia previously announced delisting notice on May 31, 2018
Jul 19, 2018 07:00 am ET
Concordia International Corp. Announces NASDAQ Delisting
Concordia previously announced delisting notice on May 31, 2018
Jun 26, 2018 10:00 am ET
Concordia International Corp. Obtains Final Court Order Approving its Recapitalization Transaction and Announces Leadership Changes
OAKVILLE, ON, June 26, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that in connection with the previously announced recapitalization transaction (the "Recapitalization Transaction") described in the Company's management information circular dated May 15, 2018, the Company has obtained a final court order (the "Final Order") from the Ontario Superior Court of Justice (Commercial List) approving the plan of arrange
Jun 26, 2018 10:00 am ET
Concordia International Corp. Obtains Final Court Order Approving its Recapitalization Transaction and Announces Leadership Changes
OAKVILLE, ON, June 26, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that in connection with the previously announced recapitalization transaction (the "Recapitalization Transaction") described in the Company's management information circular dated May 15, 2018, the Company has obtained a final court order (the "Final Order") from the Ontario Superior Court of Justice (Commercial List) approving the plan of
Jun 19, 2018 12:49 pm ET
Concordia International Corp. Announces Approval of its CBCA Plan of Arrangement by its Shareholders and Debtholders
OAKVILLE, ON, June 19, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR) today announced that at the meetings (the "Debtholders' Meetings") of holders of certain secured debt of Concordia (the "Secured Debtholders") and holders of certain unsecured debt of Concordia (the "Unsecured Debtholders") and at the annual and special meeting (the "Shareholders' Meeting" and, together with the Debtholders' Meetings, the "Meetings") of shareholders of Concordia (the "Shareholders"), the Secured Debtholders, Unsecured Debtholders and Shareholders approved the previousl
Jun 19, 2018 12:49 pm ET
Concordia International Corp. Announces Approval of its CBCA Plan of Arrangement by its Shareholders and Debtholders
OAKVILLE, ON, June 19, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR) today announced that at the meetings (the "Debtholders' Meetings") of holders of certain secured debt of Concordia (the "Secured Debtholders") and holders of certain unsecured debt of Concordia (the "Unsecured Debtholders") and at the annual and special meeting (the "Shareholders' Meeting" and, together with the Debtholders' Meetings, the "Meetings") of shareholders of Concordia (the "Shareholders"), the Secured Debtholders, Unsecured Debtholders and Shareholders approved the pr
Jun 18, 2018 08:40 am ET
Concordia International Corp. Announces Amendments to its CBCA Plan of Arrangement in Connection with its Recapitalization Transaction
OAKVILLE, ON, June 18, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR) announced today that, in connection with the previously announced proposed recapitalization transaction (the "Recapitalization Transaction") described in the Company's management information circular dated May 15, 2018 (the "Circular") and to be implemented pursuant to a plan of arrangement (the "CBCA Plan") under the Canada Business Corporations Act (the "CBCA"), the Company has, with the support of the applicable parties to the support agreement entered into in connection with the Re
Jun 18, 2018 08:40 am ET
Concordia International Corp. Announces Amendments to its CBCA Plan of Arrangement in Connection with its Recapitalization Transaction
OAKVILLE, ON, June 18, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR) announced today that, in connection with the previously announced proposed recapitalization transaction (the "Recapitalization Transaction") described in the Company's management information circular dated May 15, 2018 (the "Circular") and to be implemented pursuant to a plan of arrangement (the "CBCA Plan") under the Canada Business Corporations Act (the "CBCA"), the Company has, with the support of the applicable parties to the support agreement entered into in connection with
Jun 07, 2018 07:00 am ET
Concordia International Corp. Announces Update on Debtholder Votes and Extension of the Early Consent Date in Connection with its Recapitalization Transaction
OAKVILLE, ON, June 7, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, announced today that the Company's previously announced recapitalization transaction (the "Recapitalization Transaction") to be implemented pursuant to a plan of arrangement (the "CBCA Plan") under the Canada Business Corporations Act (the "CBCA") in Concordia's proceedings under the CBCA has received the requisite level of debtholder approvals as p
Jun 07, 2018 07:00 am ET
Concordia International Corp. Announces Update on Debtholder Votes and Extension of the Early Consent Date in Connection with its Recapitalization Transaction
OAKVILLE, ON, June 7, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, announced today that the Company's previously announced recapitalization transaction (the "Recapitalization Transaction") to be implemented pursuant to a plan of arrangement (the "CBCA Plan") under the Canada Business Corporations Act (the "CBCA") in Concordia's proceedings under the CBCA has received the requisite level of debtholder approva
May 31, 2018 07:00 am ET
Concordia International Corp. Provides Corporate Update
OAKVILLE, ON, May 31, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced a number of corporate developments.
May 31, 2018 07:00 am ET
Concordia International Corp. Provides Corporate Update
OAKVILLE, ON, May 31, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced a number of corporate developments.
May 28, 2018 07:00 am ET
Concordia International Corp. Announces Changes to its Board of Directors
OAKVILLE, ON, May 28, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that Jordan Kupinsky, Non-Executive Chairman of the Board of Directors of Concordia (the "Board"), is stepping down, effective immediately.
May 28, 2018 07:00 am ET
Concordia International Corp. Announces Changes to its Board of Directors
OAKVILLE, ON, May 28, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that Jordan Kupinsky, Non-Executive Chairman of the Board of Directors of Concordia (the "Board"), is stepping down, effective immediately.
May 17, 2018 04:47 pm ET
Concordia International Corp. Announces Filing of its Information Circular in connection with its Recapitalization Transaction and its Annual Meeting of Shareholders
OAKVILLE, ON, May 17, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, is today publicly posting and commencing the distribution of its information circular (the "Circular") for the meetings (the "Debtholders' Meetings") of holders of certain secured debt of Concordia (the "Secured Debtholders") and holders of certain unsecured debt of Concordia (the "Unsecured Debtholders") and for the annual and special meeting of sh
May 17, 2018 04:47 pm ET
Concordia International Corp. Announces Filing of its Information Circular in connection with its Recapitalization Transaction and its Annual Meeting of Shareholders
OAKVILLE, ON, May 17, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, is today publicly posting and commencing the distribution of its information circular (the "Circular") for the meetings (the "Debtholders' Meetings") of holders of certain secured debt of Concordia (the "Secured Debtholders") and holders of certain unsecured debt of Concordia (the "Unsecured Debtholders") and for the annual and special meetin
May 15, 2018 07:00 am ET
Concordia International Corp. Announces First Quarter 2018 Results
First quarter 2018 revenue of $152 million
First quarter 2018 GAAP net loss of $56 million
First quarter 2018 adjusted EBITDA1 of $72 million
Generated cash flow from operations of $51 million in the first quarter of 2018 and concluded the quarter with a cash balance of $344 million
On May 2, 2018, announced the execution of a support agreement with debtholders holding in aggregate more than 72 per cent of its affected secured debt and more than 64 per cent of its affected unsecured debt in connection with a proposed recapitalization transaction that would raise $586.5 million, and reduce
May 15, 2018 07:00 am ET
Concordia International Corp. Announces First Quarter 2018 Results
First quarter 2018 revenue of $152 million
First quarter 2018 GAAP net loss of $56 million
First quarter 2018 adjusted EBITDA1 of $72 million
Generated cash flow from operations of $51 million in the first quarter of 2018 and concluded the quarter with a cash balance of $344 million
On May 2, 2018, announced the execution of a support agreement with debtholders holding in aggregate more than 72 per cent of its affected secured debt and more than 64 per cent of its affected unsecured debt in connection with a proposed recapitalization transaction that would raise $586.5 million, and reduce
May 07, 2018 05:00 pm ET
Concordia International Corp. Announces Release Date for First Quarter 2018 Results
OAKVILLE, ON, May 7, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced it intends to release its first quarter 2018 financial results before market open on Tuesday, May 15, 2018.
May 07, 2018 05:00 pm ET
Concordia International Corp. Announces Release Date for First Quarter 2018 Results
OAKVILLE, ON, May 7, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced it intends to release its first quarter 2018 financial results before market open on Tuesday, May 15, 2018.
May 02, 2018 08:58 am ET
Concordia International Corp. Executes Support Agreement and Obtains Interim Order in Connection with its Recapitalization Transaction, and Announces Leadership Transition
Concordia announces the execution of a support agreement with debtholders holding in aggregate approximately 72 per cent of its affected secured debt and approximately 64 per cent of its affected unsecured debt in connection with a recapitalization transaction that would raise US$586.5 million and reduce the Company's outstanding debt by approximately US$2.4 billion
The recapitalization transaction would result in, among other things, affected secured debtholders receiving, in exchange for their secured claims, cash and new secured debt in an aggregate amount equal to approximately 93.4% o
May 02, 2018 08:58 am ET
Concordia International Corp. Executes Support Agreement and Obtains Interim Order in Connection with its Recapitalization Transaction, and Announces Leadership Transition
Concordia announces the execution of a support agreement with debtholders holding in aggregate approximately 72 per cent of its affected secured debt and approximately 64 per cent of its affected unsecured debt in connection with a recapitalization transaction that would raise US$586.5 million and reduce the Company's outstanding debt by approximately US$2.4 billion
The recapitalization transaction would result in, among other things, affected secured debtholders receiving, in exchange for their secured claims, cash and new secured debt in an aggregate amount equal to approximately 93.4% o
Mar 08, 2018 06:00 am ET
Concordia International Corp. Announces Fourth Quarter and Fiscal 2017 Results
2017 revenue of $626 million
2017 GAAP net loss from continuing operations of $1,591 million, which includes goodwill and intangible asset impairments totaling $1,195 million
2017 adjusted EBITDA1 of $315 million
Generated cash flow from operations of $283 million in 2017 and concluded the year with a cash balance of $327 million while pursuing a capital structure realignment through a CBCA proceeding
Reported fourth quarter 2017 revenue of $150 million and fourth quarter adjusted EBITDA1 of $71 million
Concordia today announced the final implementation of a new organization leadership
Mar 08, 2018 06:00 am ET
Concordia International Corp. Announces Fourth Quarter and Fiscal 2017 Results
2017 revenue of $626 million
2017 GAAP net loss from continuing operations of $1,591 million, which includes goodwill and intangible asset impairments totaling $1,195 million
2017 adjusted EBITDA1 of $315 million
Generated cash flow from operations of $283 million in 2017 and concluded the year with a cash balance of $327 million while pursuing a capital structure realignment through a CBCA proceeding
Reported fourth quarter 2017 revenue of $150 million and fourth quarter adjusted EBITDA1 of $71 million
Concordia today announced the final implementation of a new organization leadership
Feb 21, 2018 06:00 am ET
Concordia International Corp. Announces Release Date for Fourth Quarter and Year-End 2017 Results
OAKVILLE, ON, Feb. 21, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced it intends to issue its fourth quarter and year-end 2017 financial results via press release before market open on Thursday, March 8, 2018.
Feb 21, 2018 06:00 am ET
Concordia International Corp. Announces Release Date for Fourth Quarter and Year-End 2017 Results
OAKVILLE, ON, Feb. 21, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced it intends to issue its fourth quarter and year-end 2017 financial results via press release before market open on Thursday, March 8, 2018.
Feb 15, 2018 06:26 am ET
Concordia International Corp. Comments on CMA's Decision to Close its Investigation of Fusidic Acid
OAKVILLE, ON, Feb. 15, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that the UK Competition and Markets Authority (CMA) has notified the Company that it is closing its investigation related to Fusidic Acid eye drops.
Feb 15, 2018 06:26 am ET
Concordia International Corp. Comments on CMA's Decision to Close its Investigation of Fusidic Acid
OAKVILLE, ON, Feb. 15, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that the UK Competition and Markets Authority (CMA) has notified the Company that it is closing its investigation related to Fusidic Acid eye drops.
Dec 15, 2017 09:32 am ET
Concordia International Corp. Comments on Recent Trading Activity
OAKVILLE, ON, Dec. 15, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that at the request of the Investment Industry Regulatory Organization of Canada ("IIROC"), the Company is confirming that it is unaware at this time of any material change in its operations that would account for the recent increase in market activity.
Dec 15, 2017 09:32 am ET
Concordia International Corp. Comments on Recent Trading Activity
OAKVILLE, ON, Dec. 15, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that at the request of the Investment Industry Regulatory Organization of Canada ("IIROC"), the Company is confirming that it is unaware at this time of any material change in its operations that would account for the recent increase in market activity.
Dec 01, 2017 06:00 am ET
Concordia International Corp. Announces Receipt of Nasdaq Initial Notice of Bid Price Requirement
OAKVILLE, ON, Dec. 1, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that on November 29, 2017, it received an initial notification letter from the Listing Qualifications Department of the NASDAQ Global Select Market ("Nasdaq") notifying the Company that it had 180 days to regain compliance with the minimum bid price requirement set forth in Nasdaq's continued listing rules.
Dec 01, 2017 06:00 am ET
Concordia International Corp. Announces Receipt of Nasdaq Initial Notice of Bid Price Requirement
OAKVILLE, ON, Dec. 1, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that on November 29, 2017, it received an initial notification letter from the Listing Qualifications Department of the NASDAQ Global Select Market ("Nasdaq") notifying the Company that it had 180 days to regain compliance with the minimum bid price requirement set forth in Nasdaq's continued listing rules.
Nov 21, 2017 01:00 am ET
Concordia International Corp. Comments on CMA Statement of Objections Related to Liothyronine
- Decisions on two other Concordia medications deferred
Nov 21, 2017 01:00 am ET
Concordia International Corp. Comments on CMA Statement of Objections Related to Liothyronine
- Decisions on two other Concordia medications deferred
Nov 14, 2017 07:00 am ET
Nov 14, 2017 07:00 am ET
Nov 01, 2017 06:00 pm ET
Concordia International Corp. Announces Release Date for Third Quarter 2017 Results
OAKVILLE, ON, Nov. 1, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced it intends to release its third quarter 2017 financial results before market open on Tuesday, November 14, 2017.
Nov 01, 2017 06:00 pm ET
Concordia International Corp. Announces Release Date for Third Quarter 2017 Results
OAKVILLE, ON, Nov. 1, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced it intends to release its third quarter 2017 financial results before market open on Tuesday, November 14, 2017.
Oct 20, 2017 11:00 am ET
IIROC Trade Resumption - CXR
TORONTO, Oct. 20, 2017 /CNW/ - Trading resumes in:
Oct 20, 2017 10:47 am ET
Concordia International Corp. Takes Next Step to Realign Its Capital Structure By Commencing Proceedings Under the Canada Business Corporations Act
Concordia is seeking to reduce its existing secured and unsecured debt obligations by more than $2 billion, while significantly reducing its annual interest expense (the "Proposed Recapitalization Transaction")
Canada Business Corporations Act (the "CBCA") is a Canadian corporate statute allowing Canadian corporations to restructure certain debt obligations. The CBCA is not a bankruptcy or insolvency statute
Company intends to continue operating its business as usual during the CBCA proceedings while honouring its obligations to employees, suppliers and customers
OAKVILLE, ON, Oct. 20, 2
Oct 20, 2017 10:47 am ET
Concordia International Corp. Takes Next Step to Realign Its Capital Structure By Commencing Proceedings Under the Canada Business Corporations Act
Concordia is seeking to reduce its existing secured and unsecured debt obligations by more than $2 billion, while significantly reducing its annual interest expense (the "Proposed Recapitalization Transaction")
Canada Business Corporations Act (the "CBCA") is a Canadian corporate statute allowing Canadian corporations to restructure certain debt obligations. The CBCA is not a bankruptcy or insolvency statute
Company intends to continue operating its business as usual during the CBCA proceedings while honouring its obligations to employees, suppliers and customers
OAKVILLE, ON, Oct. 20, 2
Oct 20, 2017 10:44 am ET
IIROC Trading Halt - CXR
TORONTO, Oct. 20, 2017 /CNW/ - The following issues have been halted by IIROC:
Oct 20, 2017 09:55 am ET
IIROC Trade Resumption - Concordia International Corp.
Toronto, Ontario--(Newsfile Corp. - October 20, 2017) - Trading resumes in:
Oct 20, 2017 09:34 am ET
IIROC Trade Halt - Concordia International Corp.
Toronto, Ontario--(Newsfile Corp. - October 20, 2017) - The following issues have been halted by IIROC:
Oct 16, 2017 09:00 am ET
Concordia International Corp. Continues Discussions with Stakeholders; Defers Unsecured Interest Payment Due October 16th as It Works Toward Realignment of its Capital Structure
Company intends to operate its business as usual while continuing to honour its obligations to employees, suppliers and customers
OAKVILLE, ON, Oct. 16, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that in conjunction with its ongoing efforts to realign its capital structure, it has decided to use a 30-day grace period to defer the payment of approximately $26 million of interest due today on it
Oct 16, 2017 09:00 am ET
Concordia International Corp. Continues Discussions with Stakeholders; Defers Unsecured Interest Payment Due October 16th as It Works Toward Realignment of its Capital Structure
Company intends to operate its business as usual while continuing to honour its obligations to employees, suppliers and customers
OAKVILLE, ON, Oct. 16, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that in conjunction with its ongoing efforts to realign its capital structure, it has decided to use a 30-day grace period to defer the payment of approximately $26 million of interest due toda
Oct 11, 2017 08:00 am ET
Concordia International Corp. Announces New Communication With CMA
OAKVILLE, ON, Oct. 11, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that the UK Competition and Markets Authority (CMA) is investigating new issues in relation to the UK pharmaceutical sector, and that Concordia's International segment and certain of its products are part of the inquiry.
Oct 11, 2017 08:00 am ET
Concordia International Corp. Announces New Communication With CMA
OAKVILLE, ON, Oct. 11, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that the UK Competition and Markets Authority (CMA) is investigating new issues in relation to the UK pharmaceutical sector, and that Concordia's International segment and certain of its products are part of the inquiry.
Sep 06, 2017 08:00 am ET
Concordia International Corp. Announces DELIVER Strategy
OAKVILLE, ON, Sept. 6, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced the details of DELIVER, its long-term growth strategy.
Sep 06, 2017 08:00 am ET
Concordia International Corp. Announces DELIVER Strategy
OAKVILLE, ON, Sept. 6, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced the details of DELIVER, its long-term growth strategy.
Aug 30, 2017 06:00 pm ET
Concordia International Corp. Announces Release Date for DELIVER Strategy
OAKVILLE, ON, Aug. 30, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced it intends to disclose the details of DELIVER, its long-term growth strategy, on Wednesday, September 6, 2017 at 8:30 am ET.
Aug 30, 2017 06:00 pm ET
Concordia International Corp. Announces Release Date for DELIVER Strategy
OAKVILLE, ON, Aug. 30, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced it intends to disclose the details of DELIVER, its long-term growth strategy, on Wednesday, September 6, 2017 at 8:30 am ET.
Aug 11, 2017 08:00 am ET
Concordia International Corp. Announces Second Quarter 2017 Results
Reported second quarter revenue of $160.8 million
Reported a net loss from operations of $1.01 billion, primarily due to $987.1 million of impairments recorded on goodwill, product rights and other intangible assets
Reported second quarter adjusted EBITDA of $81.8 million
Generated cash flow from operations of $155.6 million in the first six months of 2017
Subsequent to quarter end, Concordia finalized its long-term growth strategy and intends to communicate it by mid September 2017
Concordia today announces executive leadership changes
OAKVILLE, ON, Aug. 11, 2017 /CNW/ - Concordia Inter
Aug 11, 2017 08:00 am ET
Concordia International Corp. Announces Second Quarter 2017 Results
Reported second quarter revenue of $160.8 million
Reported a net loss from operations of $1.01 billion, primarily due to $987.1 million of impairments recorded on goodwill, product rights and other intangible assets
Reported second quarter adjusted EBITDA of $81.8 million
Generated cash flow from operations of $155.6 million in the first six months of 2017
Subsequent to quarter end, Concordia finalized its long-term growth strategy and intends to communicate it by mid September 2017
Concordia today announces executive leadership changes
OAKVILLE, ON, Aug. 11, 2017 /PRNewswire/ - Concordi
Jul 28, 2017 08:00 am ET
Concordia International Announces Release Date for Second Quarter 2017 Results
OAKVILLE, ON, July 28, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced it intends to release its second quarter 2017 financial results before market open on Friday, August 11, 2017.
Jul 28, 2017 08:00 am ET
Concordia International Announces Release Date for Second Quarter 2017 Results
OAKVILLE, ON, July 28, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced it intends to release its second quarter 2017 financial results before market open on Friday, August 11, 2017.
Jun 21, 2017 08:00 am ET
Concordia International Corp. Provides Update on Development of Long-Term Growth Strategy
OAKVILLE, ON, June 21, 2017 /CNW/ - Concordia International Corp. (the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced an update on the development of its long-term growth strategy.
Jun 21, 2017 08:00 am ET
Concordia International Corp. Provides Update on Development of Long-Term Growth Strategy
OAKVILLE, ON, June 21, 2017 /PRNewswire/ - Concordia International Corp. (the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced an update on the development of its long-term growth strategy.
Jun 13, 2017 09:00 am ET
Concordia International Corp. Announces RedHill Biopharma Has Started Promoting Donnatal® in the U.S.
OAKVILLE, ON, June 13, 2017 /CNW/ - Concordia International Corp. (the "Company") (NASDAQ: CXRX) (TSX: CXR) - together with its subsidiaries ("Concordia"), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced that RedHill Biopharma Ltd. (RedHill) (NASDAQ: RDHL) (TASE: RDHL), a specialty biopharmaceutical company, has started promoting Donnatal® in certain U.S. territories.
Jun 13, 2017 09:00 am ET
Concordia International Corp. Announces RedHill Biopharma Has Started Promoting Donnatal® in the U.S.
OAKVILLE, ON, June 13, 2017 /PRNewswire/ - Concordia International Corp. (the "Company") (NASDAQ: CXRX) (TSX: CXR) - together with its subsidiaries ("Concordia"), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced that RedHill Biopharma Ltd. (RedHill) (NASDAQ: RDHL) (TASE: RDHL), a specialty biopharmaceutical company, has started promoting Donnatal® in certain U.S. territories.
Jun 09, 2017 03:29 pm ET
Concordia International Corp. Announces Results of Annual General and Special Meeting of Shareholders
OAKVILLE, ON, June 9, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held on June 9, 2017, in Oakville, Ontario.
Jun 09, 2017 03:29 pm ET
Concordia International Corp. Announces Results of Annual General and Special Meeting of Shareholders
OAKVILLE, ON, June 9, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held on June 9, 2017, in Oakville, Ontario.
May 31, 2017 08:35 am ET
Concordia International Corp. Announces Results of First CMA Stop/Go Decision
OAKVILLE, ON, May 31, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced that the UK Competition and Markets Authority (CMA) has notified the Company that it intends to continue with its pricing investigation at this time.
May 31, 2017 08:35 am ET
Concordia International Corp. Announces Results of First CMA Stop/Go Decision
OAKVILLE, ON, May 31, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced that the UK Competition and Markets Authority (CMA) has notified the Company that it intends to continue with its pricing investigation at this time.
May 10, 2017 08:00 am ET
Concordia International Corp. Announces First Quarter 2017 Results
Concordia reported first quarter revenue of $160.6 million, gross profit of $115.4 million and net loss from continuing operations of $78.8 million
The Company generated cash flow from operations of $86.2 million
Adjusted EBITDA1 in the first quarter was $84.2 million
Company executing against its 2017 business stabilization objectives
Development of long-term business strategy remains on track
Announced on April 26 that David Price appointed as CFO
Announced on May 4 that Itzhak Krinsky and Frank Perier, Jr. appointed to Board of Directors
OAKVILLE, ON, May 10, 2017 /CNW/ - Concordia
May 10, 2017 08:00 am ET
Concordia International Corp. Announces First Quarter 2017 Results
Concordia reported first quarter revenue of $160.6 million, gross profit of $115.4 million and net loss from continuing operations of $78.8 million
The Company generated cash flow from operations of $86.2 million
Adjusted EBITDA1 in the first quarter was $84.2 million
Company executing against its 2017 business stabilization objectives
Development of long-term business strategy remains on track
Announced on April 26 that David Price appointed as CFO
Announced on May 4 that Itzhak Krinsky and Frank Perier, Jr. appointed to Board of Directors
OAKVILLE, ON, May 10, 2017 /PRNewswire/ - Con
May 04, 2017 08:00 am ET
Concordia International Corp. Announces Two New Appointments to the Board of Directors
Itzhak Krinsky and Frank Perier, Jr. bring extensive pharmaceutical experience to the Board
May 04, 2017 08:00 am ET
Concordia International Corp. Announces Two New Appointments to the Board of Directors
Itzhak Krinsky and Frank Perier, Jr. bring extensive pharmaceutical experience to the Board
May 02, 2017 06:00 pm ET
Concordia International Corp. Announces Release Date for First Quarter 2017 Results
OAKVILLE, ON, May 2, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced it intends to release its first quarter 2017 financial results before market open on Wednesday, May 10, 2017.
May 02, 2017 06:00 pm ET
Concordia International Corp. Announces Release Date for First Quarter 2017 Results
OAKVILLE, ON, May 2, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced it intends to release its first quarter 2017 financial results before market open on Wednesday, May 10, 2017.
Apr 26, 2017 05:15 pm ET
Concordia International Appoints David Price as Chief Financial Officer
- Company to Conduct First Quarter Earnings Call on May 10, 2017 in the Ordinary Course
Apr 26, 2017 05:15 pm ET
Concordia International Appoints David Price as Chief Financial Officer
- Company to Conduct First Quarter Earnings Call on May 10, 2017 in the Ordinary Course
Mar 15, 2017 08:00 am ET
Concordia International Announces Fourth Quarter and Fiscal 2016 Results
2016 consolidated revenue of $816.2 million
2016 GAAP net loss from continuing operations of $1,314.1 million
2016 adjusted EBITDA1 of $468.1 million
Fourth quarter consolidated revenue of $170.4 million
Fourth quarter adjusted EBITDA1 of $80.5 million
Company establishes 2017 objectives focused on stabilizing the business
Concurrently developing long-term growth strategy
Appointed Allan Oberman as CEO
OAKVILLE, ON, March 15, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company fo
Mar 15, 2017 08:00 am ET
Concordia International Announces Fourth Quarter and Fiscal 2016 Results
2016 consolidated revenue of $816.2 million
2016 GAAP net loss from continuing operations of $1,314.1 million
2016 adjusted EBITDA1 of $468.1 million
Fourth quarter consolidated revenue of $170.4 million
Fourth quarter adjusted EBITDA1 of $80.5 million
Company establishes 2017 objectives focused on stabilizing the business
Concurrently developing long-term growth strategy
Appointed Allan Oberman as CEO
OAKVILLE, ON, March 15, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical com
Mar 09, 2017 07:00 am ET
Concordia International Corp. Announces Release Date for Fourth Quarter and Year-End 2016 Results
OAKVILLE, ON, March 9, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced it intends to release its fourth quarter and year-end 2016 financial results before market open on Wednesday, March 15, 2017.
Mar 09, 2017 07:00 am ET
Concordia International Corp. Announces Release Date for Fourth Quarter and Year-End 2016 Results
OAKVILLE, ON, March 9, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced it intends to release its fourth quarter and year-end 2016 financial results before market open on Wednesday, March 15, 2017.
Mar 06, 2017 07:00 am ET
Concordia International Corp. Grant of Treble Damages Further Vindicates Marketing Rights of its Donnatal® Brand
Damage award tripled to $2.2 million
Decision further strengthens Donnatal® brand rights
OAKVILLE, ON, March 6, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced that a U.S. district court has granted the Company treble damages related to false claims made by Method Pharmaceuticals, LLC ("Method") and its principal owner. All financial references are in U.S. dollars.
Mar 06, 2017 07:00 am ET
Concordia International Corp. Grant of Treble Damages Further Vindicates Marketing Rights of its Donnatal® Brand
Damage award tripled to $2.2 million
Decision further strengthens Donnatal® brand rights
OAKVILLE, ON, March 6, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced that a U.S. district court has granted the Company treble damages related to false claims made by Method Pharmaceuticals, LLC ("Method") and its principal owner. All financial references are in U.S. dollars.
Mar 03, 2017 08:01 am ET
Concordia International Corp. Comments on CMA Statement of Objections Related to Hydrocortisone 10mg
OAKVILLE, ON, March 3, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today commented on the issuance by the UK Competition and Markets Authority (CMA) of a Statement of Objections to Actavis UK (formerly Auden Mckenzie) and Concordia's International segment in relation to the supply of 10mg hydrocortisone tablets in the United Kingdom between 2013 and 2016.
Mar 03, 2017 08:01 am ET
Concordia International Corp. Comments on CMA Statement of Objections Related to Hydrocortisone 10mg
OAKVILLE, ON, March 3, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today commented on the issuance by the UK Competition and Markets Authority (CMA) of a Statement of Objections to Actavis UK (formerly Auden Mckenzie) and Concordia's International segment in relation to the supply of 10mg hydrocortisone tablets in the United Kingdom between 2013 and 2016.
Feb 01, 2017 07:00 am ET
Concordia International Corp. Makes Final Earn Out Payment to Cinven
OAKVILLE, ON, Feb. 1, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced that it has paid the second and final installment of its earn-out to Cinven1 relating to Concordia's October 2015 acquisition of Amdipharm Mercury Limited.
Feb 01, 2017 07:00 am ET
Concordia International Corp. Makes Final Earn Out Payment to Cinven
OAKVILLE, ON, Feb. 1, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced that it has paid the second and final installment of its earn-out to Cinven1 relating to Concordia's October 2015 acquisition of Amdipharm Mercury Limited.
Jan 03, 2017 07:00 am ET
Concordia International Corp. Announces Co-Promote Agreement for Donnatal®
Performance-based arrangement predicated on sales exceeding predetermined levels
Co-promotional agreement is consistent with Concordia's strategic focus on operational excellence
OAKVILLE, ON, Jan. 3, 2017 /CNW/ - Concordia International Corp. (the "Company") (NASDAQ: CXRX) (TSX: CXR) - together with its subsidiaries ("Concordia") - an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced it has entered into a three-year, co-promotion agreement with RedHill Biopharma Ltd. (RedHill) (NASDAQ: RDHL) (TASE: RDH
Jan 03, 2017 07:00 am ET
Concordia International Corp. Announces Co-Promote Agreement for Donnatal®
Performance-based arrangement predicated on sales exceeding predetermined levels
Co-promotional agreement is consistent with Concordia's strategic focus on operational excellence
OAKVILLE, ON, Jan. 3, 2017 /PRNewswire/ - Concordia International Corp. (the "Company") (NASDAQ: CXRX) (TSX: CXR) - together with its subsidiaries ("Concordia") - an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced it has entered into a three-year, co-promotion agreement with RedHill Biopharma Ltd. (RedHill) (NASDAQ: RDHL) (TA
Dec 28, 2016 07:00 am ET
Concordia International Corp. Announces Leadership Transition at International Segment
OAKVILLE, ON, Dec. 28, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced that effective January 1, 2017, John Beighton will retire from his current role as President of the Company's International segment.
Dec 28, 2016 07:00 am ET
Concordia International Corp. Announces Leadership Transition at International Segment
OAKVILLE, ON, Dec. 28, 2016 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced that effective January 1, 2017, John Beighton will retire from his current role as President of the Company's International segment.
Dec 19, 2016 07:00 am ET
Concordia International Corp. Provides Business Update
OAKVILLE, ON, Dec. 19, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced that the Company has paid the first installment of its earn-out to Cinven1 relating to Concordia's October 2015 acquisition of Amdipharm Mercury Limited. All financial references below are in U.S. dollars unless otherwise noted.
Dec 19, 2016 07:00 am ET
Concordia International Corp. Provides Business Update
OAKVILLE, ON, Dec. 19, 2016 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced that the Company has paid the first installment of its earn-out to Cinven1 relating to Concordia's October 2015 acquisition of Amdipharm Mercury Limited. All financial references below are in U.S. dollars unless otherwise noted.
Nov 22, 2016 11:29 am ET
IIROC Trade Resumption - CXR
TORONTO, Nov. 22, 2016 /CNW/ - Trading resumes in:
Nov 22, 2016 11:16 am ET
IIROC Trading Halt - CXR
TORONTO, Nov. 22, 2016 /CNW/ - The following issues have been halted by IIROC:
Nov 22, 2016 11:12 am ET
IIROC Trading Halt - CXR
TORONTO, Nov. 22, 2016 /CNW/ - The following issues have been halted by IIROC:
Nov 07, 2016 07:00 am ET
Concordia International Announces Third Quarter 2016 Results
OAKVILLE, ON, Nov. 7, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced its financial and operational results for the three and nine months ended September 30, 2016. All financial references are in U.S. dollars unless otherwise noted.
Nov 07, 2016 07:00 am ET
Concordia International Announces Third Quarter 2016 Results
OAKVILLE, ON, Nov. 7, 2016 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced its financial and operational results for the three and nine months ended September 30, 2016. All financial references are in U.S. dollars unless otherwise noted.
Nov 02, 2016 08:00 am ET
Concordia International announces new leadership appointments
Allan Oberman named Chief Executive Officer
Jordan Kupinsky appointed Chairman of the Board
OAKVILLE, ON, Nov. 2, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR) today announced that its Board of Directors has appointed Allan Oberman as its new Chief Executive Officer and selected Jordan Kupinsky as Chairman of the Board of Directors. The new appointments are effective November 14, 2016.
Nov 02, 2016 08:00 am ET
Concordia International announces new leadership appointments
Allan Oberman named Chief Executive Officer
Jordan Kupinsky appointed Chairman of the Board
OAKVILLE, ON, Nov. 2, 2016 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR) today announced that its Board of Directors has appointed Allan Oberman as its new Chief Executive Officer and selected Jordan Kupinsky as Chairman of the Board of Directors. The new appointments are effective November 14, 2016.
Nov 01, 2016 06:00 pm ET
Concordia International Corp. Announces Second Cross Currency Swap Agreement
OAKVILLE, ON, Nov. 1, 2016 /CNW/ - Concordia International Corp. (the "Company") (NASDAQ: CXRX) (TSX: CXR) - together with its subsidiaries ("Concordia") - an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced that it has entered into an additional cross currency swap agreement (the "Swap Agreement") as part of its ongoing currency hedging program.
Nov 01, 2016 06:00 pm ET
Concordia International Corp. Announces Second Cross Currency Swap Agreement
OAKVILLE, ON, Nov. 1, 2016 /PRNewswire/ - Concordia International Corp. (the "Company") (NASDAQ: CXRX) (TSX: CXR) - together with its subsidiaries ("Concordia") - an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced that it has entered into an additional cross currency swap agreement (the "Swap Agreement") as part of its ongoing currency hedging program.
Oct 26, 2016 06:00 pm ET
Concordia International Corp. Announces Release Date for Third Quarter 2016 Results
TORONTO, Oct. 26, 2016 /CNW/ - Concordia International Corp. ("Concordia" or "the Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced it intends to release its third quarter 2016 financial results before market open on Monday, November 7, 2016.
Oct 26, 2016 06:00 pm ET
Concordia International Corp. Announces Release Date for Third Quarter 2016 Results
TORONTO, Oct. 26, 2016 /PRNewswire/ - Concordia International Corp. ("Concordia" or "the Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced it intends to release its third quarter 2016 financial results before market open on Monday, November 7, 2016.
Oct 25, 2016 12:09 pm ET
Concordia International Corp. Announces Communication With CMA
OAKVILLE, ON, Oct. 25, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced that the UK Competition and Markets Authority (CMA) is investigating various issues in relation to the UK pharmaceutical sector, and that Concordia's International segment is part of the inquiry.
Oct 25, 2016 12:09 pm ET
Concordia International Corp. Announces Communication With CMA
OAKVILLE, ON, Oct. 25, 2016 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced that the UK Competition and Markets Authority (CMA) is investigating various issues in relation to the UK pharmaceutical sector, and that Concordia's International segment is part of the inquiry.
Oct 21, 2016 03:08 pm ET
IIROC Trade Resumption - CXR
TORONTO, Oct. 21, 2016 /CNW/ - Trading resumes in:
Oct 21, 2016 02:55 pm ET
Concordia International Corp. Announces CEO Transition Plan
OAKVILLE, ON, Oct. 21, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR) today announced that Mark L. Thompson will step down as Chief Executive Officer of the Company following the appointment of a successor.
Oct 21, 2016 02:55 pm ET
Concordia International Corp. Announces CEO Transition Plan
OAKVILLE, ON, Oct. 21, 2016 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR) today announced that Mark L. Thompson will step down as Chief Executive Officer of the Company following the appointment of a successor.
Oct 21, 2016 02:54 pm ET
IIROC Trading Halt - CXR
TORONTO, Oct. 21, 2016 /CNW/ - The following issues have been halted by IIROC:
Oct 13, 2016 01:23 pm ET
Concordia International Announces Closing of Senior Notes Offering and Appoints Allan Oberman to Board of Directors
OAKVILLE, ON, Oct. 13, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced the closing of its previously disclosed offering (the "Offering") of 5 ½ year Senior Secured First Lien Notes (the "Notes").
Oct 13, 2016 01:23 pm ET
Concordia International Announces Closing of Senior Notes Offering and Appoints Allan Oberman to Board of Directors
OAKVILLE, ON, Oct. 13, 2016 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced the closing of its previously disclosed offering (the "Offering") of 5 ½ year Senior Secured First Lien Notes (the "Notes").
Oct 06, 2016 06:51 pm ET
Concordia International Announces Pricing of Offering of Senior Notes
OAKVILLE, ON, Oct. 6, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced the pricing of its previously disclosed offering (the "Offering") of 5 ½ year Senior Secured First Lien Notes (the "Notes").
Oct 06, 2016 06:51 pm ET
Concordia International Announces Pricing of Offering of Senior Notes
OAKVILLE, ON, Oct. 6, 2016 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced the pricing of its previously disclosed offering (the "Offering") of 5 ½ year Senior Secured First Lien Notes (the "Notes").
Oct 05, 2016 05:31 pm ET
Concordia International Announces Offering of Senior Notes
OAKVILLE, ON, Oct. 5, 2016 /CNW/ - Concordia International Corp. (Concordia or the Company) (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced its intention to commence an offering (the "Offering"), subject to market conditions and other factors, of up to $350 million of new 5 ½ year Senior Secured First Lien Notes (the "Notes").
Oct 05, 2016 05:31 pm ET
Concordia International Announces Offering of Senior Notes
OAKVILLE, ON, Oct. 5, 2016 /PRNewswire/ - Concordia International Corp. (Concordia or the Company) (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced its intention to commence an offering (the "Offering"), subject to market conditions and other factors, of up to $350 million of new 5 ½ year Senior Secured First Lien Notes (the "Notes").
Oct 03, 2016 08:51 am ET
Concordia International Exercises Option to Defer Portion of Earn-Out and Provides Update on Strategic Review
OAKVILLE, ON, Oct. 3, 2016 /CNW/ - Concordia International Corp. (the "Company") (NASDAQ: CXRX) (TSX: CXR) – together with its subsidiaries ("Concordia") - an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced that it has exercised an option to defer half of the anticipated £144 million earn-out obligation due to Cinven1 and the other sellers of Concordia's International segment, to February 1, 2017.
Oct 03, 2016 08:51 am ET
Concordia International Exercises Option to Defer Portion of Earn-Out and Provides Update on Strategic Review
OAKVILLE, ON, Oct. 3, 2016 /PRNewswire/ - Concordia International Corp. (the "Company") (NASDAQ: CXRX) (TSX: CXR) – together with its subsidiaries ("Concordia") - an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced that it has exercised an option to defer half of the anticipated £144 million earn-out obligation due to Cinven1 and the other sellers of Concordia's International segment, to February 1, 2017.
Sep 16, 2016 11:01 am ET
Concordia International Comments on Health Service Medical Supplies (Costs) Bill
OAKVILLE, ON, Sept. 16, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today commented on the UK's Health Service Medical Supplies (Costs) Bill, which was introduced into the House of Commons on September 15, 2016. The proposed bill would amend and extend existing provisions of the National Health Service Act 2006 to help manage the cost of health service medicines.
Sep 16, 2016 11:01 am ET
Concordia International Comments on Health Service Medical Supplies (Costs) Bill
OAKVILLE, ON, Sept. 16, 2016 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today commented on the UK's Health Service Medical Supplies (Costs) Bill, which was introduced into the House of Commons on September 15, 2016. The proposed bill would amend and extend existing provisions of the National Health Service Act 2006 to help manage the cost of health service medicines.
Sep 09, 2016 06:15 pm ET
S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian Indices
The Annual Review of the S&P/TSX SmallCap Index
Sep 09, 2016 06:15 pm ET
S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian Indices
Results of the Quarterly Review of the S&P/TSX Composite Index
Aug 22, 2016 06:00 pm ET
Concordia International Corp. Issues Statement On Sale Of Company Stock
OAKVILLE, ON, Aug. 22, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, stated that Concordia's Chairman and Chief Executive Officer Mark Thompson was notified earlier today of the sale of 505,000 of his shares as part of a margin call.
Aug 22, 2016 06:00 pm ET
Concordia International Corp. Issues Statement On Sale Of Company Stock
OAKVILLE, ON, Aug. 22, 2016 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, stated that Concordia's Chairman and Chief Executive Officer Mark Thompson was notified earlier today of the sale of 505,000 of his shares as part of a margin call.
Aug 17, 2016 11:00 am ET
Shareholder Class Action Filed Against Concordia International Corp. - CXRX
RADNOR, Pa., Aug. 17, 2016 /CNW/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed against Concordia International Corp. (NASDAQ:CXRX) (TSX:CRX) ("Concordia" or the "Company") on behalf of purchasers of the Company's securities between November 12, 2015 and August 12, 2016, inclusive (the "Class Period").
Aug 17, 2016 11:00 am ET
Shareholder Class Action Filed Against Concordia International Corp. - CXRX
RADNOR, Pa., Aug. 17, 2016 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed against Concordia International Corp. (NASDAQ:CXRX) (TSX:CRX) ("Concordia" or the "Company") on behalf of purchasers of the Company's securities between November 12, 2015 and August 12, 2016, inclusive (the "Class Period").
Aug 15, 2016 02:15 pm ET
Concordia International Corp. Announces Cross Currency Swap Agreement
OAKVILLE, ON, Aug. 15, 2016 /CNW/ - Concordia International Corp. (the "Company") (NASDAQ: CXRX) (TSX: CXR) - together with its subsidiaries ("Concordia") - an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced that it has entered into a cross currency swap agreement (the "Swap Agreement").
Aug 15, 2016 02:15 pm ET
Concordia International Corp. Announces Cross Currency Swap Agreement
OAKVILLE, ON, Aug. 15, 2016 /PRNewswire/ - Concordia International Corp. (the "Company") (NASDAQ: CXRX) (TSX: CXR) - together with its subsidiaries ("Concordia") - an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced that it has entered into a cross currency swap agreement (the "Swap Agreement").
Aug 12, 2016 08:00 am ET
Concordia International Announces Second Quarter 2016 Results
Second quarter 2016 revenue of $231.7 million, an increase of 1.4 per cent over the first quarter of 2016 and 208 per cent over the second quarter of 2015
Reported second quarter GAAP net loss of $570.5 million, GAAP earnings per share loss of $11.18, which was primarily due to an adjustment to the carrying values of Nilandron® and Plaquenil® by $567 million due to generic competition
Second quarter 2016 adjusted EBITDA1 of $142.3 million and adjusted earnings per share of $1.38
Concordia's International segment launched 13 new products since October 21, 2015; the Company remains on t
Aug 12, 2016 08:00 am ET
Concordia International Announces Second Quarter 2016 Results
Second quarter 2016 revenue of $231.7 million, an increase of 1.4 per cent over the first quarter of 2016 and 208 per cent over the second quarter of 2015
Reported second quarter GAAP net loss of $570.5 million, GAAP earnings per share loss of $11.18, which was primarily due to an adjustment to the carrying values of Nilandron® and Plaquenil® by $567 million due to generic competition
Second quarter 2016 adjusted EBITDA1 of $142.3 million and adjusted earnings per share of $1.38
Concordia's International segment launched 13 new products since October 21, 2015; the Company remains on t
Aug 03, 2016 10:24 am ET
Concordia International Corp. Confirms That Strategic Review is Ongoing and Provides Update on its Business
OAKVILLE, ON, Aug. 3, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today confirmed that its review of strategic alternatives is ongoing and provided an update on its business.
Aug 03, 2016 10:24 am ET
Concordia International Corp. Confirms That Strategic Review is Ongoing and Provides Update on its Business
OAKVILLE, ON, Aug. 3, 2016 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today confirmed that its review of strategic alternatives is ongoing and provided an update on its business.
Jul 19, 2016 03:00 pm ET
Concordia International Announces Release Date for Second Quarter 2016 Results
TORONTO, July 19, 2016 /CNW/ - Concordia International Corp. ("Concordia" or "the Company") (NASDAQ: CXRX) (TSX: CXR) today announced it intends to release its second quarter 2016 financial results before market open on Friday, August 12, 2016.
Jul 19, 2016 03:00 pm ET
Concordia International Announces Release Date for Second Quarter 2016 Results
TORONTO, July 19, 2016 /PRNewswire/ - Concordia International Corp. ("Concordia" or "the Company") (NASDAQ: CXRX) (TSX: CXR) today announced it intends to release its second quarter 2016 financial results before market open on Friday, August 12, 2016.
Jul 13, 2016 06:00 pm ET
Concordia International Corp. Provides Additional Disclosure in Relation to Brexit's Impact on its Business
OAKVILLE, ON, July 13, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today provided an update to its June 28, 2016 press release relating to the potential impact on the Company's financial operations of the United Kingdom's referendum to withdraw from the European Union ("Brexit").
Jul 13, 2016 06:00 pm ET
Concordia International Corp. Provides Additional Disclosure in Relation to Brexit's Impact on its Business
OAKVILLE, ON, July 13, 2016 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today provided an update to its June 28, 2016 press release relating to the potential impact on the Company's financial operations of the United Kingdom's referendum to withdraw from the European Union ("Brexit").
Jun 30, 2016 08:00 am ET
Concordia International Corp. Announces FDA Approval for New Photofrin® Laser
OAKVILLE, ON, June 30, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced that the U.S. Food and Drug Administration has approved the Company's premarket approval application (PMA) for its new Photofrin® 630 PDT Laser.
Jun 30, 2016 08:00 am ET
Concordia International Corp. Announces FDA Approval for New Photofrin® Laser
OAKVILLE, ON, June 30, 2016 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced that the U.S. Food and Drug Administration has approved the Company's premarket approval application (PMA) for its new Photofrin® 630 PDT Laser.
Jun 28, 2016 08:00 am ET
Concordia Healthcare Corp. Announces Name Change to Concordia International Corp. and Comments on Brexit's Impact on the Company's Business
OAKVILLE, ON, June 28, 2016 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced it has changed its name to Concordia International Corp.
Jun 28, 2016 08:00 am ET
Concordia Healthcare Corp. Announces Name Change to Concordia International Corp. and Comments on Brexit's Impact on the Company's Business
OAKVILLE, ON, June 28, 2016 /PRNewswire/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced it has changed its name to Concordia International Corp.
Jun 17, 2016 06:00 pm ET
Concordia Healthcare Announces PDT with Photofrin® Data and Provides Corporate Update
OAKVILLE, ON, June 17, 2016 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced positive findings from an analysis of Photodynamic Therapy (PDT) with Photofrin® clinical data and also provided a corporate update.
Jun 17, 2016 06:00 pm ET
Concordia Healthcare Announces PDT with Photofrin® Data and Provides Corporate Update
OAKVILLE, ON, June 17, 2016 /PRNewswire/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced positive findings from an analysis of Photodynamic Therapy (PDT) with Photofrin® clinical data and also provided a corporate update.
Jun 02, 2016 04:08 pm ET
Concordia Healthcare Confirms That Review of Strategic Alternatives Ongoing
OAKVILLE, ON, June 2, 2016 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, confirmed today that its review of strategic alternatives is ongoing.
Jun 02, 2016 04:08 pm ET
Concordia Healthcare Confirms That Review of Strategic Alternatives Ongoing
OAKVILLE, ON, June 2, 2016 /PRNewswire/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, confirmed today that its review of strategic alternatives is ongoing.
Jun 02, 2016 02:44 pm ET
IIROC Trade Resumption - CXR
TORONTO, June 2, 2016 /CNW/ - Trading resumes in:
Jun 02, 2016 02:36 pm ET
IIROC Trading Halt - CXR
TORONTO, June 2, 2016 /CNW/ - The following issues have been halted by IIROC:
Jun 01, 2016 08:22 pm ET
Concordia Healthcare Completes Acquisition of Four Generic Products
OAKVILLE, ON, June 1, 2016 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, announced today that it has completed the acquisition of the global rights to four generic products, as previously announced on May 13, 2016.
Jun 01, 2016 08:22 pm ET
Concordia Healthcare Completes Acquisition of Four Generic Products
OAKVILLE, ON, June 1, 2016 /PRNewswire/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, announced today that it has completed the acquisition of the global rights to four generic products, as previously announced on May 13, 2016.
May 13, 2016 07:00 am ET
Concordia Healthcare Announces First Quarter 2016 Results and Acquisition of Four Products with Global Rights
First quarter 2016 revenue of $228.5 million, an increase of 19 per cent over the fourth quarter of 2015 and 570 per cent over the first quarter in 2015
First quarter 2016 adjusted EBITDA1 of $140.8 million, an increase of 17 per cent over the fourth quarter of 2015 and 631 per cent over the first quarter in 2015
Subsequent to quarter end, entered into an agreement to acquire four products that add to the Company's diverse product mix
Concordia International segment launched 10 new products since October 21, 2015; the Company remains on track to meet its target of 60 plus launches in the
May 13, 2016 07:00 am ET
Concordia Healthcare Announces First Quarter 2016 Results and Acquisition of Four Products with Global Rights
First quarter 2016 revenue of $228.5 million, an increase of 19 per cent over the fourth quarter of 2015 and 570 per cent over the first quarter in 2015
First quarter 2016 adjusted EBITDA1 of $140.8 million, an increase of 17 per cent over the fourth quarter of 2015 and 631 per cent over the first quarter in 2015
Subsequent to quarter end, entered into an agreement to acquire four products that add to the Company's diverse product mix
Concordia International segment launched 10 new products since October 21, 2015; the Company remains on track to meet its target of 60 plus launches in the
Apr 29, 2016 07:15 pm ET
Concordia Healthcare Reports Results of Annual General and Special Meeting of Shareholders
OAKVILLE, ON, April 29, 2016 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (TSX: CXR) (NASDAQ: CXRX), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, announced today the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held on April 29, 2016, in Toronto, Ontario.
Apr 29, 2016 07:15 pm ET
Concordia Healthcare Reports Results of Annual General and Special Meeting of Shareholders
OAKVILLE, ON, April 29, 2016 /PRNewswire/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (TSX: CXR) (NASDAQ: CXRX), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, announced today the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held on April 29, 2016, in Toronto, Ontario.
Apr 22, 2016 09:14 am ET
IIROC Trade Resumption - CXR
TORONTO, April 22, 2016 /CNW/ - Trading resumes in:
Apr 21, 2016 05:25 pm ET
Concordia Healthcare Announces Formation of Special Committee to Review Strategic Alternatives
OAKVILLE, ON, April 21, 2016 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced it has formed a special committee of independent members of the Board of Directors of the Company (the "Special Committee") to consider various strategic alternatives potentially available to the Company.
Apr 21, 2016 05:25 pm ET
Concordia Healthcare Announces Formation of Special Committee to Review Strategic Alternatives
OAKVILLE, ON, April 21, 2016 /PRNewswire/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced it has formed a special committee of independent members of the Board of Directors of the Company (the "Special Committee") to consider various strategic alternatives potentially available to the Company.
Apr 21, 2016 03:04 pm ET
IIROC Trading Halt - CXR
TORONTO, April 21, 2016 /CNW/ - The following issues have been halted by IIROC:
Apr 21, 2016 02:45 pm ET
IIROC Trade Resumption - CXR
TORONTO, April 21, 2016 /CNW/ - Trading resumes in:
Apr 21, 2016 02:38 pm ET
IIROC Trading Halt - CXR
TORONTO, April 21, 2016 /CNW/ - The following issues have been halted by IIROC:
Apr 19, 2016 03:55 pm ET
Concordia Healthcare Announces Release Date for First Quarter 2016 Results
TORONTO, April 19, 2016 /CNW/ - Concordia Healthcare Corp. ("Concordia" or "the Company") NASDAQ: CXRX) (TSX: CXR) today announced it intends to release its first quarter 2016 financial results before market open on Friday, May 13, 2016.
Apr 19, 2016 03:55 pm ET
Concordia Healthcare Announces Release Date for First Quarter 2016 Results
TORONTO, April 19, 2016 /PRNewswire/ - Concordia Healthcare Corp. ("Concordia" or "the Company") NASDAQ: CXRX) (TSX: CXR) today announced it intends to release its first quarter 2016 financial results before market open on Friday, May 13, 2016.
Mar 29, 2016 07:00 am ET
Concordia Healthcare Corrects Inaccurate Report
OAKVILLE, ON, March 29, 2016 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced that it is providing information to correct inaccuracies and misstatements that appeared in a recent media report concerning its 2015 audited financial results.
Mar 29, 2016 07:00 am ET
Concordia Healthcare Corrects Inaccurate Report
OAKVILLE, ON, March 29, 2016 /PRNewswire/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced that it is providing information to correct inaccuracies and misstatements that appeared in a recent media report concerning its 2015 audited financial results.
Mar 23, 2016 06:00 pm ET
Concordia Healthcare Announces Fourth Quarter and Fiscal 2015 Results and Board Appointment
Achieves global scale, providing patients with products in 100+ counties
Year-over-year revenue growth of $289 million or an increase of 276 per cent
Year-over-year adjusted EBITDA1 growth of $206 million or an increase of 347 per cent
Reaffirms guidance2 of $1,020 million to $1,060 million in revenue and adjusted EBITDA1 of $610 million to $640 million
OAKVILLE, ON, March 23, 2016 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, tod
Mar 23, 2016 06:00 pm ET
Concordia Healthcare Announces Fourth Quarter and Fiscal 2015 Results and Board Appointment
Achieves global scale, providing patients with products in 100+ counties
Year-over-year revenue growth of $289 million or an increase of 276 per cent
Year-over-year adjusted EBITDA1 growth of $206 million or an increase of 347 per cent
Reaffirms guidance2 of $1,020 million to $1,060 million in revenue and adjusted EBITDA1 of $610 million to $640 million
OAKVILLE, ON, March 23, 2016 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, tod
Feb 16, 2016 07:00 am ET
Concordia Healthcare Announces Addition to Senior Executive Team, Presentation at RBC Investor Conference, and Release Date for Fourth Quarter and 2015 Results
OAKVILLE, ON, Feb. 16, 2016 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, announced today that Edward Borkowski, currently a member of Concordia's Board of Directors, will join the organization as Executive Vice President.
Feb 16, 2016 07:00 am ET
Concordia Healthcare Announces Addition to Senior Executive Team, Presentation at RBC Investor Conference, and Release Date for Fourth Quarter and 2015 Results
OAKVILLE, ON, Feb. 16, 2016 /PRNewswire/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, announced today that Edward Borkowski, currently a member of Concordia's Board of Directors, will join the organization as Executive Vice President.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
